(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 May 2015 (07.05.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/066551 A3

(51) **International Patent Classification**:
C07K 16/46 (2006.01) *C07K 14/705* (2006.01)
C12P 21/00 (2006.01) *C07K 16/28* (2006.01)

(21) **International Application Number**:
PCT/US2014/063576

(22) **International Filing Date**:
31 October 2014 (31.10.2014)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/898,387 31 October 2013 (31.10.2013) US

(71) **Applicants**: **FRED HUTCHINSON CANCER RESEARCH CENTER** [US/US]; 1100 Fairview Avenue North, J2-302, Seattle, Washington 98109 (US). **SEATTLE CHILDREN'S HOSPITAL, D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE** [US/US]; 1900 9th Avenue, Seattle, Washington 98101 (US).

(72) **Inventors**: **DELANEY, Colleen**; 3224 East Mercer Street, Seattle, Washington 98112 (US). **JENSEN, Michael**; 3494 Pleasant Beach Drive, Bainbridge Island, Washington 98110 (US). **GARDNER, Rebecca**; 19429 12th Ave NW, Shoreline, Washington 98177 (US).

(74) **Agents**: **WINGER, C. Rachal** et al.; Lee & Hayes, PLLC, 601 W. Riverside Ave, Suite 1400, Spokane, Washington 99201 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) **Date of publication of the international search report**:
25 June 2015

WO 2015/066551 A3

(54) **Title**: MODIFIED HEMATOPOIETIC STEM/PROGENITOR AND NON-T EFFECTOR CELLS, AND USES THEREOF

(57) **Abstract**: Hematopoeitic stem/progenitor cells (HSPC) and/or non-T effector cells are genetically modified to express (i) an extracellular component including a ligand binding domain that binds a cellular marker preferentially expressed on an unwanted cell; and (ii) an intracellular component comprising an effector domain. Among other uses, the modified cells can be administered to patients to target unwanted cancer cells without the need for immunological matching before administration.